![Janneke de Wal](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Janneke de Wal
Nessuna posizione attualmente
Storia della carriera di Janneke de Wal
Precedenti posizioni note di Janneke de Wal
Società | Posizione | Inizio | Fine |
---|---|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
![]() Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Vendite & Marketing | 01/08/2008 | 11/03/2013 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Vendite & Marketing | - | - |
Formazione di Janneke de Wal
University of Leiden | Doctorate Degree |
Statistiche
Distribuzione geografica
Paesi Bassi | 3 |
Stati Uniti | 2 |
Posizioni
Sales & Marketing | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Commercial Services | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
![]() Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Janneke de Wal
- Esperienza